Cortisol inhibition – a potential new approach to treating Alzheimer’s disease


Published 29-JUN-2016 14:50 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Data on a potential breakthrough treatment for Alzheimer’s disease (AD), based on excess cortisol regulation in the human brain, will be presented at the Alzheimer’s Association International Conference (AAIC), held in Toronto, Canada in July.

The company behind the novel, cortisol-focused approach is Actinogen Medical (ASX:ACW), an ASX-listed biotech company that’s just recently entered Stage 2 clinical trials evaluating Xanamem as a promising new treatment for mild Alzheimer’s disease.

The invitation for ACW to present its findings and ongoing research at AAIC, is a first step for ACW to publicise its research on Xanamem, alongside the growing understanding of the serious impact of excess cortisol on the human brain

ACW will present a talk titled, “XanamemTM a novel 11β–HSD1 inhibitor with potential to provide durable symptomatic and disease modifying benefits in Alzheimer’s disease”. The presentation is expected to include the latest results on XanamemTM, ACW’s flagship pharmaceutical product that could prove to be a significant new treatment for Alzheimer’s disease.

One of the first major hurdles in proving the efficacy of Xanamem, was confirming the drug’s ability to cross the blood-brain barrier. ACW successfully achieved this milestone and has now launched an in-depth Phase 2 drug trial in mild Alzheimer’s disease, called XanADu.

A further important study being presented at AAIC, will present data supporting ACW’s overarching hypothesis on the adverse effects of cortisol on the human brain. Data from a landmark study undertaken by the independent AIBL Research Group in Australia, demonstrates the clear association between excess cortisol and the development of Alzheimer’s disease.

The AIBL study is funded by various Australian government agencies and universities, including the CSIRO, and strongly endorses the cortisol hypothesis that underlies the development of XanamemTM as a treatment option for Alzheimer’s disease.

ACW will begin an extensive series of presentations and data publications over the coming 6 months, advancing its “cortisol hypothesis” and publicising its work. More publicity could potentially serve as price catalysts for ACW, currently priced at $0.075 per share and valued at A$46 million by market capitalisation.

Dr. Bill Ketelbey, CEO of Actinogen Medical.

“We eagerly anticipate these trials being presented to the worldwide medical and scientific community, at such a prestigious forum. This will be the first broad-based exposure of these results, in advance of their publication later this year. This exciting new data on Xanamem, alongside the strongly supportive AIBL results linking excess cortisol with Alzheimer’s disease, provides powerful independent endorsement for Actinogen’s development of XanamemTM in Alzheimer’s disease,” said Dr. Bill Ketelbey, CEO of Actinogen Medical.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free